证券代码：002004 证券简称：华邦健康 公告编号：2026005 华邦生命健康股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 特此公告。 华邦生命健康股份有限公司 1 项 目 本报告期 上年同期 归属于上市公司 股东的净利润 盈利：66,000.00 万元-73,000.00 万元 亏损：29,898.99 万元 比上年同期增长: 320.74%-344.16% 扣除非经常性损 益后的净利润 盈利：60,000.00 万元-67,000.00 万元 亏损：33,785.22 万元 比上年同期增长：277.59%-298.31% 基本每股收益 盈利：0.3345 元/股-0.3700 元/股 亏损：0.1514 元/股 （二）业绩预告情况：预计净利润为正值且属于扭亏为盈情形 开拓市场，加强精细化管理，降本增效，整体业绩得到改善和提升；公司医药、 旅游等板块亦实现了业绩稳步增长，共同推动公司整体业绩稳步增长。 四、其他相关说明 本次业绩预告数据是公司财务部门初步估算得出，尚未经审计机构审计， 2025 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.77% on January 20, with Kangzhi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hanshang Group (Code: 600774) with a closing price of 11.64, up 10.02% and a trading volume of 438,600 shares, totaling 489 million yuan [1] - Tainkang (Code: 301263) with a closing price of 32.71, up 7.04% and a trading volume of 138,300 shares, totaling 437 million yuan [1] - Sitaili (Code: 603520) with a closing price of 10.58, up 2.52% and a trading volume of 210,900 shares, totaling 225 million yuan [1] - Conversely, significant decliners included: - Kangyi Pharmaceutical (Code: 300086) with a closing price of 10.44, down 5.86% and a trading volume of 447,100 shares [2] - Dizhe Pharmaceutical (Code: 688192) with a closing price of 62.72, down 5.10% and a trading volume of 42,700 shares [2] - Guangji Pharmaceutical (Code: 000952) with a closing price of 7.52, down 4.93% and a trading volume of 292,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.348 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.109 billion yuan [2] - The capital flow for specific stocks indicated: - Huabang Health (Code: 002004) had a net inflow of 88.38 million yuan from institutional investors, but a net outflow of 73.07 million yuan from retail investors [3] - Fuxiang Pharmaceutical (Code: 300497) recorded a net inflow of 57.88 million yuan from institutional investors, with a net outflow of 102 million yuan from retail investors [3] - Xinqiao Pharmaceutical (Code: 000756) had a net inflow of 25.08 million yuan from institutional investors, but also saw a net outflow of 15.54 million yuan from retail investors [3]

Group 1 - The core point of the announcement is that the actual controller of Huabang Life Health Co., Ltd., Mr. Zhang Songshan, has notified the company about the release of a portion of his pledged shares [1] - The announcement includes details about the basic situation of the release of the pledge and the cumulative pledge situation of Mr. Zhang Songshan and his concerted actors [1] - As of the date of the announcement, the pledged shares held by Mr. Zhang Songshan and his concerted actors, including Chongqing Huibang Zhuoyuan Technology Co., Ltd., Zhang Yizhuo, and Zhao Danlin, are specified [1]

证券代码：002004 证券简称：华邦健康 公告编号：2026004 华邦生命健康股份有限公司 关于实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于近日接到公司实际控制人 张松山先生的通知，获悉其将所持有本公司的部分股份办理解除质押业务,具体 情况如下： 一、本次解除质押基本情况 | 股东 | 是否为控股股东或第一大 | 本次解除质押股 | 占其所持股份 | 占公司总股 | 质押起始日 | 解除质押日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股东及其一致行动人 | 份数量（股） | 比例 | 本比例 | | | | | 张松山 | 是 | 32,000,000 | 27.33% | 1.62% | 2025.03.21 | 2026.01.16 | 渤海国际信托 股份有限公司 | 二、张松山先生及其一致行动人股份累计质押基本情况 特此公告。 华邦生命健康股份有限公司 董 事 会 2026 年 ...

Group 1: Report Core Information - The report regularly tracks the latest private exchangeable bond (private EB) projects from public channels and focuses on basic elements, reminding that the issuance terms and progress may change, with the final prospectus and inquiries to the lead underwriters being the basis [1] Group 2: New Project Information This Week - Huabang Life - Health Co., Ltd.'s 2026 private placement of innovative technology - exchangeable corporate bonds for professional investors has been accepted by the exchange, with an intended issuance scale of 1 billion yuan, the underlying stock being Kaisheng New Materials (301069.SZ), and the lead underwriters being Huatai United and Southwest Securities, updated on January 16, 2026 [1] Group 3: Project Status Summary - There are multiple private EB projects in different statuses, including "Passed", "Received Feedback", and "Accepted". For example, projects of Shanxi Transportation Development and Investment Group Co., Ltd., Fuda Holdings Group Co., Ltd. etc. have passed; projects of Hainan农垦 Investment and Holding Group Co., Ltd., Strait Innovation Internet Co., Ltd. etc. have received feedback; projects of Huabang Life - Health Co., Ltd., Northern Lingyun Industry Group Co., Ltd. etc. have been accepted [3]

Core Viewpoint - Huabang Health is experiencing a significant stock price increase, reflecting positive market sentiment and potential growth opportunities in the pharmaceutical and AI healthcare sectors [1] Company Overview - Huabang Health's main business includes the research, production, and sales of pharmaceutical formulations, active pharmaceutical ingredients, and pesticides, as well as pharmaceutical distribution and import-export trade [1] - The company is a leading player in the domestic clinical dermatology market and is exploring AI healthcare-related business directions through its subsidiaries [1] Industry Developments - The Morgan Stanley Healthcare Conference in San Francisco has highlighted significant investments in AI drug development, with Nvidia and Eli Lilly committing $1 billion over five years to establish a joint research lab [1] - The National Healthcare Security Administration is seeking public opinion on guidelines for the comprehensive value assessment of drugs in real-world settings, which aims to provide guidance for high-quality development in the pharmaceutical industry [1] - Continuous policy support for pharmaceutical R&D innovation and the acceleration of AI healthcare innovations are fostering a conducive environment for industry growth [1]

Core Viewpoint - The announcement details the pledge of shares by the controlling shareholder of Huabang Health, indicating that the pledged shares do not involve any major asset restructuring or performance compensation obligations [1][3]. Group 1: Pledge Details - The controlling shareholder, Chongqing Huibang Zhuoyuan Technology Co., Ltd., has notified the company about the pledge of part of its shares [1]. - The pledged shares do not carry significant asset restructuring or performance compensation obligations [1]. - The total number of pledged shares by Huibang Zhuoyuan and its concerted actors is significant, with 116,600,000 shares maturing in the next six months, representing 21.47% of their total holdings and 5.89% of the company's total share capital [2]. Group 2: Financial Implications - The financing balance corresponding to the shares maturing in the next six months is approximately 20.895 million [2]. - In the next year, a total of 296,720,000 shares will mature, accounting for 54.64% of their total holdings and 14.99% of the company's total share capital, with a financing balance of about 58.545 million [2]. - The shareholders have the financial capability to repay the financing, with funds sourced from their own or self-raised resources [2]. Group 3: Impact on Company Operations - The share pledges have not adversely affected the company's operations or governance [3]. - There are no indications of non-operating fund occupation or illegal guarantees that would harm the interests of the listed company [2].

Group 1 - The core viewpoint of the article is that Huabang Health has committed to fulfilling its information disclosure obligations in accordance with relevant laws and regulations, and investors are advised to pay attention to the company's announcements [2]

证券代码：002004 证券简称：华邦健康 公告编号：2026003 华邦生命健康股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于近日接到公司控股股东重 庆汇邦卓远科技有限公司（以下简称"汇邦卓远"）的通知，获悉其将所持有本公 司的部分股份办理质押业务,具体情况如下： 一、本次质押基本情况 三、其他说明 1、汇邦卓远本次股份质押担保融资不用于满足上市公司生产经营相关需求。 2、汇邦卓远及其一致行动人张松山先生、张一卓先生、赵丹琳女士未来半 年及未来一年质押到期情况：（1）汇邦卓远及其一致行动人张松山先生、张一卓 先生、赵丹琳女士在未来半年内（2026 年 1 月 14 日-2026 年 7 月 13 日）到期的 质押股份数量累计为 116,600,000 股，占其合计持有公司股份的比例为 21.47%， 占公司总股本的比例为 5.89%，对应融资余额为 20,895 万元；（2）汇邦卓远及其 一致行动人张松山先生、张一卓先生、赵丹琳女士在未来一年内（2026 年 1 月 ...

Group 1 - The controlling shareholder Huibang Zhuoyuan has pledged 27.73 million shares, accounting for 7.49% of its holdings and 1.40% of the company's total share capital [1] - As of the announcement date, Huibang Zhuoyuan and its concerted parties have pledged a total of 297 million shares, representing 54.64% of their combined holdings and 14.99% of the company's total share capital [1] - Within the next six months, 117 million pledged shares are set to mature, corresponding to a financing balance of 209 million yuan; within the next year, 297 million pledged shares are due, with a financing balance of 585 million yuan [1]